Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Immunicum AB announced that members of the management team will attend and present at upcoming conferences in March and April.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
BioArctic AB comments on the decision by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2018 and its outlook for 2019.
Galapagos NV announces a share capital increase arising from warrant exercises.
Only a few months after GlaxoSmithKline acquired Waltham, Mass.-based Tesaro, Tesaro released promising data from its Phase I/II GARNET study of dostarlimab in endometrial cancer.
This morning Starboard Value LP issued an investor presentation opposing the proposed deal. The group will share the materials with other shareholders in hopes to sway support for its opposition.
Alcon said the acquisition of PowerVision demonstrates its commitment to bringing advanced technology intraocular lenses to cataract patients across the globe.
Polyphor AG (SIX: POLN), a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds announced its financial results for the full-year of 2018.
Auris Medical Holding AG announced that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission.